Frontline Drugs Vancomycin, Fidaxomicin Found to Benefit Transplant Patients With C Difficile
Adult patients with Clostrioides difficile infection who received hematopoietic stem cell transplant also benefitted from frontline medications fidaxomicin or oral vancomycin.
Preprint Research on Pfizer COVID-19 Vaccine Shows Greater Efficacy Two Weeks Post Administration
New data from an unreviewed, preprint research article indicate first-dose immunization efficacy of the Pfizer-BioNTech coronavirus 2019 vaccine improves by 51% 13-24 days post administration.
Sanofi to Aid in Production of Pfizer-BioNTech Vaccine
Sanofi has agreed to bottle and package at least 125 million doses of the COVID-19 vaccine BNT162b2 from Pfizer and BioNTech.
Inmazeb Gets First FDA Approval for Ebola Treatment
Atoltivimab, maftivimab, and odesivimab-ebgn (Inmazeb), a monoclonal antibody cocktail ffor the treatment of adult and pediatric patients with Ebola virus infection, becomes the first drug approved to treat Ebola virus.
Expert Panel Updates the Race for a COVID-19 Vaccine
There is no perfect moment to timestamp the accelerated, massive movement toward finding and distributing the first vaccine candidates for the coronavirus 2019 pandemic.
Improving Adherence to PrEP in At-Risk Patients
Regional and state access assistance, improved research and collaboration, and individualized options for patients are key factors in adherence to PrEP.
Asthma Watch: Trelegy Ellipta Hits Phase 3 Asthma Marks, Eyes New Indication
Pivotal phase 3 trial results show benefits for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy Ellipta) in patients with uncontrolled asthma compared with standard FF/VI (Breo Ellipta) therapy.
Trellegy Ellipta Hits Phase 3 Asthma Marks, Eyes New Indication
Gene Expression Mapping of ALS Could Reveal New Treatment Targets
The matching of optimized technologies and novel approaches has provided investigators with a framework to assess and understand neurologic conditions.
Aclidinium Bromide/Formoterol Fumarate Combo Receives FDA Approval for COPD Maintenance
The combination therapy was approved for twice-daily administration via the breath-actuated Pressair inhaler in patients with COPD.
What is the Most Cost-Effective Plaque Psoriasis Treatment?
Approximately 1.7 million insured US patients are burdened with moderate to severe plaque psoriasis.
Dupilumab Found to Significantly Improve Symptoms of Atopic Dermatitis
Biologic dupilumab plus non-cosmetic topical moisturizer associated with significantly improved symptoms and health-related quality of life in particular patients with atopic dermatitis.
Biologic Drug Shows Promise Treating Moderate-to-Severe Psoriasis
Tildrakizumab was approved by the FDA as a subcutaneous therapy for patients with moderate-to-severe psoriasis.
Analysis: Dupilumab Improves Quality of Life for Patients With Atopic Dermatitis
Analysis of care in a routine clinical practice setting show that 40-week treatment of biologic dupilumab (Dupixent, Sanofi-Regeneron) plus noncosmetic topical moisturizer (emollient) is associated with significantly improved symptoms and health-related quality of life (HRQoL) in particular patients with atopic dermatitis (AD).
Adverse Effect-Related Deaths Decline in United States
From 1990 to 2016, the rate of deaths due to adverse effects of medical treatment decreased 21.4% in the United States.
Guselkumab Shows Superiority in Severe Plaque Psoriasis
Patients administered guselkumab achieved an improvement of 90% or more Psoriasis Area Severity Index score than those administered secukinumab.
HCV Reinfection Rates Higher in Drug Users Despite Treatment
A recent study found further evidence that hepatitis C reinfection rates are greater in drug users despite successful treatment with direct-acting antiviral therapy.
Ocrelizumab Lowers Patient Risk of Upper Extremity Disability in PPMS
New study finds that ocrelizumab (Ocrevus) has the capability to reduce risk of upper extremity disability progression in patients with primary progressive multiple sclerosis (PPMS).
FDA OKs Eltrombopag Indication for Adult, Pediatric Severe Aplastic Anemia
The FDA expanded the label for eltrombopag (Promacta) to now include indication for adults and pediatric patients 2 years and older with severe aplastic anemia in combination with standard immunosuppressive therapy.
FDA Approves First Brilinta Generic
The US Food and Drug Administration (FDA) has approved the first generic medication indicated for lowering the risk of heart attack, or death from heart attack or stroke in patients with acute coronary syndrome (ACS).
FDA Warning: Cases of Genital Infections Reported with SGLT2 Inhibitors
The FDA has released a warning on cases of rare, serious genital area infections having been reported with sodium-glucose contransporter-2 (SGLT2) inhibitors.
FDA Officials Warn About Potential for Genital Infection Caused by Certain Diabetes Drugs
FDA officials are requiring a warning about this on the prescription information.
FDA OKs Ivacaftor for Treatment of Cystic Fibrosis in Young Children
Officials with the FDA have approved ivacaftor (KALYDECO) as the first and only therapy indicated to treat the underlying cause of cystic fibrosis in children aged 12 to
FDA Grants Breakthrough Designation to Omalizumab for Food Allergies
The designation was based on data from 7 clinical trials over the past decade, which assessed omalizumab’s efficacy and safety versus various food allergens, such as peanut, milk, and egg.
FDA Accepts Nasal Spray NDA for Acute Cluster Seizure Treatment
Midazolam Nasal Sprayâ€”from global biopharmaceutical company UCB, Brussels, Belgium (UCB)â€”has been previously granted Orphan Drug and Fast Track designations by the FDA
FDA Oks Methylphenidate PM Formulation for ADHD in Patients Aged 6 and Up
FDA OKs Assays for Use with Hepatitis B Diagnostic System
The FDA has granted approval to a pair of assays designated for the use with an immunodiagnostic system that detects hepatitis B (HBV) in individuals.
FDA Approves 14-Day Continuous Glucose Monitoring System
The FDA has approved the longest-lasting self-applied continuous glucose monitor (CGM) in the United States market.
FDA Approves Treatment for Thrombocytopenia in Adults with Chronic Liver Disease
The FDA has approved lusutrombopag (Mulpleta) for the treatment of thrombocytopenia in particular adults with chronic liver disease.
FDA OKs Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease
Each group reported a thrombosis-related adverse event rate of 1.9%.
2 Clarke Drive Cranbury, NJ 08512